The dominant story at M — Med Life S.A., Romania's largest private healthcare network — is one of relentless insider selling against a stock that has quietly doubled off its 2025 lows.
CEO and Chairman Mihail Marcu has been a consistent seller for the past eighteen months. He offloaded 1 million shares in January 2025 at RON 5.78, another million in March at RON 5.80, 2 million in July at RON 6.75, a further million in September at RON 7.54, and most recently 700,000 shares in January 2026 at RON 11.50. His brother Nicolae Marcu, on the Executive Board, has sold alongside him at each major step up — 500,000 shares in January 2025, 1.65 million in May, and another 500,000 in November. Together the two founders have monetised well over 9 million shares across this rally. The pattern is systematic, not panicked: each tranche priced higher than the last, tracking the stock's ascent rather than fleeing it. Even so, net insider activity over the past 90 days remains firmly in sell territory — roughly $3.9 million of net disposals as of January 2026.
What makes this interesting is where the stock now trades. Med Life closed Tuesday at RON 11.46, down nearly 2% on the week and 4.5% over the past month after hitting what appears to be a local high around RON 12. That means the CEO's most recent sale at RON 11.50 was almost perfectly timed at the top of the recent range — whether by design or coincidence, the optics are uncomfortable for new buyers. The founding family still holds substantial stakes — Mihail Marcu at roughly 12.6% and Nicolae at 9.8% — so the selling reflects position-trimming rather than an exit, but the cadence and the pricing precision are worth noting.
EPS momentum is the clearest counterweight to the insider signal. The forward earnings picture ranks near the top of the universe — the 12-month forward EPS growth estimate scores in the 98th percentile of all stocks tracked by ORTEX, and 90-day EPS momentum lands in the 85th percentile. That combination points to a business where analysts are actively raising their numbers, not cutting them. Three analysts maintain a hold consensus as of late May, with no recent rating changes on record. The PE multiple, at around 42x, has compressed slightly over the past month — down roughly 2.4 turns in 30 days — though it remains elevated by European healthcare standards. EV/EBITDA of 14.3x is more moderate, and has drifted up slightly over the month as the enterprise value expanded.
The lending market is a non-story for now. Cost-to-borrow and availability data in the system are both significantly stale — the most recent CTB reading dates to early 2024, and availability data to mid-2024 — so no reliable read is available on current short positioning. What the factor scores do confirm is a short score ranking in the 71st percentile, meaning the ORTEX short framework sees Med Life as less squeezable and less heavily positioned than most of its peers. That's consistent with the picture of a low-liquidity, founder-dominated Romanian micro-cap where shorting is structurally difficult.
Ownership is concentrated in a way that gives the stock an unusual character. The top five holders — two Marcu family members, Romanian pension fund NN (13.3%), MetLife Investment Management (7.9%), and International Finance Corporation (4.5%) — together account for over 55% of shares. Institutional flow from international names like Vanguard and Goldman Sachs is marginal in size. This is effectively a private-equity-style structure listed on BVB, which explains the thin liquidity, the sporadic borrow market, and the outsized influence of insider decisions on price discovery.
The next scheduled results date is 28 August. Between now and then, the question worth tracking is whether the Marcu family returns to sell into any further strength — and whether the exceptional EPS momentum score translates into a meaningful upward revision cycle that could give new buyers a fundamental anchor at current multiples.
See the live data behind this article on ORTEX.
Open M on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
